Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Who Is Hims Not For
BPC-157 is not FDA approved for general medical use, so patients should avoid self-sourcing or guessing their own protocol
Retatrutide is currently in Phase 3 clinical development under the TRIUMPH program, which includes obesity, type 2 diabetes, osteoarthritis-related weight outcomes, and MASLD endpoints
For those seeking a less invasive option, GLP-1 injections like Ozempic offer a powerful alternative with proven results at a fraction of the cost of surgery
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease
Storage: Protecting Your Research Investment Reconstitution is only half the battle
US$ 23.51
US$ 22.20
US$ 27.12
US$ 27.25
US$ 28.32
US$ 28.62
US$ 29.74
US$ 23.38
US$ 26.91
US$ 24.27
US$ 28.12
US$ 29.46
